Patient characteristics and treatment pathways in patients with COPD initiated on ICS/LABA/LAMA and LABA/LAMA treatment

Study identification

• EU PAS number:
  EUPAS106491
• Study ID:
  106492
• Official title and acronym:
  Patient characteristics and treatment pathways in patients with COPD initiated on ICS/LABA/LAMA and LABA/LAMA treatment
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  A historical cohort study to describe patient characteristics and 5-year treatment pathways prior to initiation on ICS/LABA/LAMA (triple therapy) and LABA/LAMA (dual bronchodilator) therapy in real-world clinical settings in the United Kingdom
• Study status:
  Finalised

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Networks

Optimum Patient Care (OPC) Network

United Kingdom (Northern Ireland)

Study timelines

Date when funding contract was signed

Planned:18/10/2022

Actual:13/10/2022

Study start date

Planned:18/10/2022

Actual:10/10/2022

Date of final study report

Planned:29/02/2024

Actual:19/04/2024

Sources of funding

Other

Pharmaceutical company and other private sector 

More details on funding

Chiesi Pharma, OPRI

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable